Fig. 3: Specific synergism of BZB with BCL-2 inhibition. | Cell Death & Disease

Fig. 3: Specific synergism of BZB with BCL-2 inhibition.

From: The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA

Fig. 3

RD and SW982 cells were incubated with 5 nM BZB and/or 15 µM of the BCL-xL inhibitor A-1155463 (a, b) or 15 µM of the MCL-1 inhibitor A-1210477 (c, d). After 24 h, exposure of phosphatidylserine (a, c) and loss of mitochondrial membrane potential (b, d) were analyzed by flow cytometric staining with Annexin V and TMRM, respectively.

Back to article page